Copyright
©The Author(s) 2015.
World J Diabetes. Jun 25, 2015; 6(6): 774-781
Published online Jun 25, 2015. doi: 10.4239/wjd.v6.i6.774
Published online Jun 25, 2015. doi: 10.4239/wjd.v6.i6.774
Table 2 Plasma half-lives, dosage ranges, average hemoglobin A1c reduction and common side effects of dipeptidyl peptidase-4 inhibitors
Drug | Plasma half-life | Dose | HbA1c reduction | Adverse effects | Other remarks |
Sitagliptin | 12.4 h | 100 mg PO daily | 0.94% | Nasopharyngitis, diarrhea, headache, constipation, oedema, hypersensitivity, pancreatitis, elevation of hepatic enzymes | Use with caution in renal, hepatic or cardiac failure |
Vildagliptin | 90 mts - by terminal elimination | 50-100 mg/daily PO | 0.5%-1% | Headache, nasopharyngitis, cough, constipation, dizziness, and increased sweating | |
Saxagliptin | 2.5 h | 2.5-5 mg/PO daily | 0.8% | Urinary and upper respiratory infections, headache, edema, purpuric rash, hypersensitivity, pancreatitis and angio-edema | Dose reduction with CYP450 3A4/5 inhibitors |
Linagliptin | 12 h | 5 mg PO daily | 0.6%-0.8% | Nasopharyngitis, dyslipidemia, pancreatitis | |
Teneligliptin | 24.2 h | 20-40 mg PO daily | 0.78% | Constipation, QT interval prolongation, hypoglycaemia and elevation of alanine aminotransferase and γ-glutamyltransferas | |
Alogliptin | 21 h | 25 mg PO daily | 0.6% | Hypoglycemia, nasopharyngitis, headache and pancreatitis | Monitor LFT and stop if elevated |
Anagliptin | 4.37 h - by terminal elimination | 100 mg PO daily | 0.85% | Not available |
- Citation: Pappachan JM, Raveendran A, Sriraman R. Incretin manipulation in diabetes management. World J Diabetes 2015; 6(6): 774-781
- URL: https://www.wjgnet.com/1948-9358/full/v6/i6/774.htm
- DOI: https://dx.doi.org/10.4239/wjd.v6.i6.774